Acme United (ACU) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Mar, 2026Executive summary
The 2026 Annual Meeting will be held virtually on April 27, 2026, with shareholders able to vote and submit questions online.
Shareholders of record as of March 10, 2026, are entitled to vote on four main proposals, including director elections and amendments to the stock option plan.
The Board recommends voting in favor of all proposals and emphasizes the importance of shareholder participation.
Voting matters and shareholder proposals
Election of seven directors for one-year terms.
Proposal to amend the 2022 Employee Stock Option Plan, increasing authorized shares from 500,000 to 700,000.
Advisory vote on executive compensation (say-on-pay).
Ratification of CBIZ CPAs, P.C. as independent auditor for fiscal year ending December 31, 2026.
Shareholder proposals for the 2027 meeting must be submitted by November 30, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Board consists of seven members, with five deemed independent under NYSE American rules.
CEO and Chairman roles are combined; no lead independent director.
Standing committees: Executive, Audit, Compensation, and Nominating, all comprised of independent directors.
Board emphasizes diversity in skills, background, and experience for director nominees.
Shareholders can nominate directors with proper notice and may communicate directly with the Board.
Latest events from Acme United
- Q2 2026 sales rose 16% with margin gains, led by My Medic and strong segment growth.ACU
Q2 2026 - First aid and safety drive growth, targeting $300M revenue in three years with global expansion.ACU
Sidoti Micro-Cap Virtual Conference - Innovation and acquisitions fuel robust growth in sales, earnings, and market expansion.ACU
Investor presentation - All proposals, including board elections and stock plan amendments, were approved by majority vote.ACU
AGM 2026 - Q1 2026 sales up 14%, but net income down 40% as higher costs and tariffs offset gains.ACU
Q1 2026 - Record 2025 results and Q4 growth, with acquisitions and investments fueling future expansion.ACU
Q4 2025 - Q2 net income up 29% on higher sales and margin, with Elite First Aid acquisition completed.ACU
Q2 2024 - Q1 2025 sales and EPS rose on first-aid strength, despite tariff and supply chain headwinds.ACU
Q1 2025 - Record sales and margin gains in 2024 driven by first-aid growth and strategic acquisitions.ACU
Q4 2024